122 related articles for article (PubMed ID: 36621146)
1. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease.
Laserna-Mendieta EJ; Salvador-Martín S; Arias A; López-Cauce B; Marín-Jiménez I; Menchén LA; Marín-Rubio L; Ontañón Rodríguez J; López-Fernández LA; Lucendo AJ
Biomed Pharmacother; 2023 Mar; 159():114225. PubMed ID: 36621146
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease.
Urabe S; Isomoto H; Ishida T; Maeda K; Inamine T; Kondo S; Higuchi N; Sato K; Uehara R; Yajima H; Machida H; Chen CC; Fukuda Y; Takeshima F; Nakao K; Tsukamoto K
Biomed Res Int; 2015; 2015():416838. PubMed ID: 26558270
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
4. HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients.
Shimoda F; Naito T; Kakuta Y; Kawai Y; Tokunaga K; ; Shimoyama Y; Moroi R; Shiga H; Nagasaki M; Kinouchi Y; Masamune A
Pharmacogenomics J; 2023 Nov; 23(6):141-148. PubMed ID: 37460671
[TBL] [Abstract][Full Text] [Related]
5. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.
Steenholdt C; Enevold C; Ainsworth MA; Brynskov J; Thomsen OØ; Bendtzen K
Aliment Pharmacol Ther; 2012 Oct; 36(7):650-9. PubMed ID: 22860894
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
8. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
9. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
10. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study.
Park SH; Hwang SW; Kwak MS; Kim WS; Lee JM; Lee HS; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yoon YS; Yu CS; Kim JH; Yang SK
Dig Dis Sci; 2016 Jul; 61(7):2060-7. PubMed ID: 26971089
[TBL] [Abstract][Full Text] [Related]
13. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
[TBL] [Abstract][Full Text] [Related]
14. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease.
Salvador-Martín S; López-Cauce B; Nuñez O; Laserna-Mendieta EJ; García MI; Lobato E; Abarca-Zabalía J; Sanjurjo-Saez M; Lucendo AJ; Marín-Jiménez I; Menchén LA; López-Fernández LA
Pharmacol Res; 2019 Nov; 149():104478. PubMed ID: 31605784
[TBL] [Abstract][Full Text] [Related]
15. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
[TBL] [Abstract][Full Text] [Related]
16. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
17. Infliximab response associates with radiologic findings in bio-naïve Crohn's disease.
Yueying C; Jing F; Qi F; Jun S
Eur Radiol; 2023 Aug; 33(8):5247-5257. PubMed ID: 36928565
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
[TBL] [Abstract][Full Text] [Related]
19. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease.
Park SH; Hong M; Lee HS; Ye BD; Hwang SW; Jung S; Baek J; Moon JW; Kim BM; Oh SH; Kim KM; Lee I; Im CN; Liu J; McGovern DPB; Yang SK; Song K
J Gastroenterol Hepatol; 2019 Dec; 34(12):2118-2125. PubMed ID: 31039275
[TBL] [Abstract][Full Text] [Related]
20. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
